RhumbLine Advisers
KYTX icon

RhumbLine Advisers’s Kyverna Therapeutics KYTX Stock Holding History

RhumbLine Advisers’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Buy
+50,188
New +$446K ﹤0.01% 2843
2025
Q2 		– Sell
-31,614
Closed -$61K – 4283
2025
Q1 		$61K Buy
31,614
+5,694
+22% +$16.8K ﹤0.01% 3532
2024
Q4 		$96.9K Buy
25,920
+6,153
+31% +$29.5K ﹤0.01% 3482
2024
Q3 		$96.7K Sell
19,767
-240
-1% -$1.85K ﹤0.01% 3508
2024
Q2 		$150K Buy
+20,007
New +$306K ﹤0.01% 3378

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

RhumbLine Advisers's KYTX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 50,188 shares worth $447K. The stake represents ﹤0.01% of the portfolio and ranks #2843 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in KYTX as recently as Q1 2025.

RhumbLine Advisers first reported a position in KYTX in Q2 2024 and has held it in 5 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • RhumbLine Advisers held 50,188 shares of Kyverna Therapeutics worth $447K as of Q2 2026.
  • Kyverna Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2843 holding.
  • RhumbLine Advisers first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.